Detalhe da pesquisa
1.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Invest New Drugs
; 41(2): 284-295, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36867316
2.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
3.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Br J Cancer
; 124(4): 744-753, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33311588
4.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850381
5.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Br J Cancer
; 116(12): 1505-1512, 2017 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28463960
6.
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Cancer Res
; 82(14): 2552-2564, 2022 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35584009
7.
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
J Med Chem
; 65(19): 13052-13073, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178776
8.
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Clin Cancer Res
; 28(4): 770-780, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782366
9.
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
Leuk Lymphoma
; 62(7): 1740-1748, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586590
10.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Blood Adv
; 5(22): 4762-4770, 2021 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34581757
11.
Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.
Onkologie
; 32(4): 175-80, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19372712
12.
Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro.
Tissue Eng
; 13(1): 111-21, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17518585
13.
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
Clin Cancer Res
; 11(12): 4561-70, 2005 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15958642
14.
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Cancer Res
; 62(20): 5785-91, 2002 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12384539
15.
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
Leuk Lymphoma
; 62(4): 999-1002, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325309
16.
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Blood Cancer J
; 11(9): 149, 2021 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480019
17.
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Clin Lymphoma Myeloma
; 6(2): 131-5, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16231851
18.
Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers - comparison of ELISA and microsphere-based multiplexed immunoassay.
Clin Chem Lab Med
; 46(9): 1256-64, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18681833
19.
Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.
Cancer Immunol Immunother
; 56(12): 1911-20, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17487487
20.
Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Stem Cells
; 25(1): 228-35, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17204607